Recent trends in ocular oncology.

Document Type


Publication Date



This article has been peer reviewed. It was published in: Oman journal of ophthalmology.

Volume 4, Issue 3, September 2011, Pages 103-4.

The published version is available at DOI: 10.4103/0974-620X.91263. Copyright © MedKnow.


New and exciting treatment options have emerged in the field of ocular oncology. Despite these novel therapeutic options, it is important to consider if a new treatment modality is truly beneficial over a proven standard treatment. Various factors such as patient features, tumor features, and benefit–risk potential should be carefully assessed in every individual case to determine which patients or tumors will directly benefit from a specific treatment. Therapeutic options of ocular tumors have evolved from observation, cryotherapy, laser therapy, systemic/intralesional steroids, topical antimetabolites, wide surgical excision, systemic chemotherapy, enucleation, and exenteration to more recent options of systemic/topical beta-blockers, topical imiquimod (IMQ), topical/intralesional interferon alpha-2b (IFNα2b), systemic/intralesional rituximab, photodynamic therapy (PDT), superselective intraophthalmic artery chemotherapy (IAC), gamma knife radiosurgery, and cyber knife radiosurgery over the past few years. Herein, we discuss the recent trends in the management of eyelid, conjunctival, intraocular, and orbital tumors.

PubMed ID